UBS raises Teva price target - Globes
Teva Plummets on Downgrade Following $85M Opioid Settlement - TheStreet
AMD, Nike, Zillow among UBS stock picks with the 'highest conviction' for 2023 - MarketWatch
Teva hires ex-Novartis executive to succeed CEO Schultz | Reuters
Teva cut to Sell at UBS citing uncertainty over leadership transition (NYSE: TEVA) | Seeking Alpha
Teva shares hit 19-year low after opioid settlement, analyst downgrades | Fierce Pharma
Teva says vaccine makers have not taken its offer to help produce jabs | Financial Times
Quest upgraded while Teva downgraded at UBS, and VectiveBio scores two new buy initiations in today's analyst action - ADVFN
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva Tries to Put an End to the Opioid Wars - WSJ
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Teva stock downgraded to neutral by UBS on heels of $85 million opioid settlement - MarketWatch
Teva Pharmaceuticals Archives - Drug Discovery and Development
$4.4 Billion Opioid Settlement Gives Teva Stock a Boost | Barron's
Generic Drug Lawsuit Could Mean Big Fines for Teva, Mylan: UBS
Summer of Teva: The Mom Comfort Sandal
Teva Pharmaceutical Industries Stock Jumps on a Rare Bullish View | Barron's
Rebounding Teva is 'too cheap to ignore,' upbeat analysts say | Fierce Pharma
Teva in Talks to Buy Allergan's Generic-Drug Unit - WSJ
Teva Pharmaceuticals Could Face Billions in Damages From Opioid Lawsuits | Barron's
